Mereo BioPharma Group PLC

MREO

Company Profile

  • Business description

    Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

  • Contact

    One Cavendish Place
    4th Floor
    LondonW1G 0QF
    GBR

    T: +44 3330237300

    E: [email protected]

    https://www.mereobiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    36

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,456.2090.501.08%
CAC 407,770.48176.612.33%
DAX 4023,057.34560.362.49%
Dow JONES (US)41,217.14464.181.14%
FTSE 1008,596.3599.551.17%
HKSE22,504.68385.271.74%
NASDAQ17,971.37260.631.47%
Nikkei 22536,830.69378.391.04%
NZX 50 Index12,327.89179.291.48%
S&P 5005,678.1874.041.32%
S&P/ASX 2008,238.0092.401.13%
SSE Composite Index3,279.037.62-0.23%

Market Movers